Literature DB >> 15013868

Factor XII deficiency: a thrombophilic risk factor for retinal vein occlusion.

Claudia Kuhli1, Inge Scharrer, Frank Koch, Christian Ohrloff, Lars-Olof Hattenbach.   

Abstract

PURPOSE: Factor XII deficiency is among the coagulation disorders that have been implicated in major thromboembolic events. However, little is known about an association of this coagulation disorder and retinal vessel occlusion. In the current study, we investigated the prevalence of factor XII deficiency in patients with retinal vein occlusion (RVO) with reference to age and cardiovascular risk factors.
DESIGN: Cross-sectional study.
METHODS: A cohort of 150 consecutive patients with central or branch retinal vein occlusion and 135 subjects matched for age and gender were prospectively screened for factor XII deficiency. Both cohorts were divided into two subgroups (<= 45 or >45 years), depending on the patients' age at the time of the RVO or a previous thromboembolic event.
RESULTS: Overall, factor XII deficiency was found to be present in 14 (9.3%) of 150 patients and in 1 (0.7%) of 135 controls (P =.0009). Patient age <= 45 years at the time of the RVO or a previous thromboembolic event was associated with a high prevalence of factor XII deficiency (18%). By contrast, only 5 (5%) of 100 patients >45 years (P =.016) and none of the young controls (P =.0001) tested positive for factor XII deficiency. The prevalence among patients >45 years was similar to that found in age-matched controls (2%; P =.66).
CONCLUSIONS: Our results indicate that factor XII deficiency is highly prevalent in RVO patients <= 45 years of age. By contrast, the prevalence of factor XII deficiency in RVO patients older than 45 years appears to be similar to that seen in healthy individuals.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15013868     DOI: 10.1016/j.ajo.2003.10.024

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  16 in total

1.  [Thrombophilic and systemic risk factors in patients with retinal vein occlusion].

Authors:  C Kuhli-Hattenbach; W Miesbach; I Scharrer; L-O Hattenbach
Journal:  Ophthalmologe       Date:  2011-02       Impact factor: 1.059

2.  Retinal vascular occlusions: an interdisciplinary challenge.

Authors:  Alireza Mirshahi; Nicolas Feltgen; Lutz L Hansen; Lars-Olof Hattenbach
Journal:  Dtsch Arztebl Int       Date:  2008-06-27       Impact factor: 5.594

3.  Sequence variation and genetic evolution at the human F12 locus: mapping quantitative trait nucleotides that influence FXII plasma levels.

Authors:  Francesc Calafell; Laura Almasy; Maria Sabater-Lleal; Alfonso Buil; Carolina Mordillo; Anna Ramírez-Soriano; Martin Sikora; Juan Carlos Souto; John Blangero; Jordi Fontcuberta; José Manuel Soria
Journal:  Hum Mol Genet       Date:  2009-11-23       Impact factor: 6.150

4.  Factor XII promotes blood coagulation independent of factor XI in the presence of long-chain polyphosphates.

Authors:  C Puy; E I Tucker; Z C Wong; D Gailani; S A Smith; S H Choi; J H Morrissey; A Gruber; O J T McCarty
Journal:  J Thromb Haemost       Date:  2013-07       Impact factor: 5.824

5.  [Multiple thrombophilic risk markers in patients ≺65 years of age with retinal vein occlusion].

Authors:  C Kuhli-Hattenbach; P Hellstern; W Miesbach; T Kohnen; L-O Hattenbach
Journal:  Ophthalmologe       Date:  2017-12       Impact factor: 1.059

6.  Acute hyperhomocysteinemia alters the coagulation system and oxidative status in the blood of rats.

Authors:  Aline A da Cunha; Emilene Scherer; Maira J da Cunha; Felipe Schmitz; Fernanda R Machado; Daniela D Lima; Débora Delwing; Angela T S Wyse
Journal:  Mol Cell Biochem       Date:  2011-09-23       Impact factor: 3.396

7.  Sudden retinal vein thrombosis in a patient with nephrotic syndrome.

Authors:  Ibrahim Masoodi; Imtiyaz Ahmad Wani; Shabnum Hussain; M S Najar; A R Reshi; Farroq A Qurashi; Shaima Khan
Journal:  BMJ Case Rep       Date:  2011-03-10

8.  Retinal vein occlusion: evaluation of "classic" and "emerging" risk factors and treatment.

Authors:  Marina Turello; Samantha Pasca; Roberto Daminato; Patrizia Dello Russo; Roberta Giacomello; Ugo Venturelli; Giovanni Barillari
Journal:  J Thromb Thrombolysis       Date:  2010-05       Impact factor: 2.300

9.  Prevalent factor XII deficiency in cancer patients with isolated aPTT prolongation.

Authors:  Dong-Yeop Shin; Hyo-Rak Lee; Hye Jin Kang; Im Il Na; Yoon Hwan Chang; Sung Hyun Yang
Journal:  Blood Res       Date:  2015-06-25

10.  Deep venous thrombosis and previous myocardial infarction in mild factor XII deficiency: a risk factor for both venous and arterial thrombosis.

Authors:  Gianfranco Lessiani; Angela Falco; Elvira Nicolucci; Giancarlo Rolandi; Giovanni Davì
Journal:  J Thromb Thrombolysis       Date:  2008-04-06       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.